Literature DB >> 15156195

Depletion of physiological levels of the human TID1 protein renders cancer cell lines resistant to apoptosis mediated by multiple exogenous stimuli.

Kirsten M Edwards1, Karl Münger.   

Abstract

The human homologue of the Drosophila tumor suppressor lethal (2) tumorous imaginal discs (l(2)tid) gene, hTID1, encodes two proteins derived from alternate mRNA splicing. The splice variants TidL and TidS were previously reported from protein overexpression and dominant-negative mutant protein studies to exhibit opposing biological activities in response to exogenous cytotoxic stimuli. TidL was found to promote apoptosis while TidS suppressed it. To elucidate the physiological function of hTID1, we depleted hTID1 proteins using the technique of RNA interference (RNAi). Here, we show that cells essentially lacking expression of hTID1 proteins are protected from cell death in response to multiple stimuli, including cisplatin, tumor necrosis factor alpha/cycloheximide and mitomycin C. We also generated stable cell populations depleted of hTID1 proteins by RNAi using DNA vectors. In addition to apoptosis resistance, stable hTID1 knockdown cells exhibited an enhanced ability for anchorage-independent growth, as measured by an increase in soft-agar colony formation. These results suggest that hTID1 functions as an important cell death regulator and raise the interesting possibility that hTID1 could exert tumor suppressor activity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15156195     DOI: 10.1038/sj.onc.1207732

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  15 in total

1.  Activation of Erk by sonic hedgehog independent of canonical hedgehog signalling.

Authors:  Hong Chang; Qing Li; Ricardo C Moraes; Michael T Lewis; Paul A Hamel
Journal:  Int J Biochem Cell Biol       Date:  2010-05-06       Impact factor: 5.085

2.  DNAJB6 chaperones PP2A mediated dephosphorylation of GSK3β to downregulate β-catenin transcription target, osteopontin.

Authors:  A Mitra; M E Menezes; L K Pannell; M S Mulekar; R E Honkanen; L A Shevde; R S Samant
Journal:  Oncogene       Date:  2012-01-23       Impact factor: 9.867

3.  Tid1 is a Smad-binding protein that can modulate Smad7 activity in developing embryos.

Authors:  Ingrid Torregroza; Todd Evans
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

4.  Beta-Amyloid Increases the Expression Levels of Tid1 Responsible for Neuronal Cell Death and Amyloid Beta Production.

Authors:  Chunyu Zhou; Ferdous Taslima; Mona Abdelhamid; Sung-Woo Kim; Hiroyasu Akatsu; Makoto Michikawa; Cha-Gyun Jung
Journal:  Mol Neurobiol       Date:  2019-11-04       Impact factor: 5.590

5.  Molecular mechanism of hTid-1, the human homolog of Drosophila tumor suppressor l(2)Tid, in the regulation of NF-kappaB activity and suppression of tumor growth.

Authors:  Hua Cheng; Carlo Cenciarelli; Gina Nelkin; Rachel Tsan; Dominic Fan; Cecilia Cheng-Mayer; Isaiah J Fidler
Journal:  Mol Cell Biol       Date:  2005-01       Impact factor: 4.272

6.  A p-Median approach for predicting drug response in tumour cells.

Authors:  Elisabetta Fersini; Enza Messina; Francesco Archetti
Journal:  BMC Bioinformatics       Date:  2014-10-29       Impact factor: 3.169

7.  The tumor suppressor hTid1 inhibits STAT5b activity via functional interaction.

Authors:  Isabelle Dhennin-Duthille; Rémy Nyga; Saliha Yahiaoui; Valérie Gouilleux-Gruart; Aline Régnier; Kaïss Lassoued; Fabrice Gouilleux
Journal:  J Biol Chem       Date:  2010-11-24       Impact factor: 5.157

Review 8.  Multi-faceted role of HSP40 in cancer.

Authors:  Aparna Mitra; Lalita A Shevde; Rajeev S Samant
Journal:  Clin Exp Metastasis       Date:  2009-04-02       Impact factor: 5.150

9.  hTID-1 defines a novel regulator of c-Met Receptor signaling in renal cell carcinomas.

Authors:  E Copeland; S Balgobin; C M Lee; M Rozakis-Adcock
Journal:  Oncogene       Date:  2011-01-17       Impact factor: 9.867

10.  In vivo evidence of htid suppressive activity on ErbB-2 in breast cancers over expressing the receptor.

Authors:  Ursula Kurzik-Dumke; Manuela Hörner; Maria R Nicotra; Michael Koslowski; Pier G Natali
Journal:  J Transl Med       Date:  2010-06-17       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.